GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding GRI Bio, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 10 | 8 | −2 |
| Shares | 222.0K | 263.6K | +41.6K (+18.7%) |
| Value | $141.0K | $74.0K | −$67.0K (−47.5%) |
New holders (3)
Institutions that held GRI Bio, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 130,239 | $37.0K | 0.00% |
| State Street Corp | 18,921 | $5.00K | 0.00% |
| FMR LLC | 10,000 | $3.00K | 0.00% |
Sold out (5)
Institutions that held GRI Bio, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Renaissance Technologies LLC | 78,888 | $50.0K |
| Two Sigma Investments, LP | 42,392 | $27.0K |
| Citigroup Inc | 6,000 | $4.00K |
| North Star Investment Management Corp. | 1,750 | $1.00K |
| Morgan Stanley | 50 | $0 |